抄録
Preventive effect of EG626 on atherosclerosis of cholesterol-fed rabbits has been shown in this experiment with 30 male adult rabbits. The placebo control group of 15 animals was given a capsule with potato-starch and the treated group of the same number of animals was given daily a capsule with EG626 (1mg/kg) once a day and all animals were kept on 1% cholesterol pellet for 16 weeks. At the end of 16 weeks of the treatment, all animals were sacrificed for the chemical and histological analysis.
The cholesterol content of aortic wall was significantly smaller in the treated group (24.0±7μg/mg D.W.) than that of the placebo control gorup (57.5±9μg/mg D.W.) (P<0.01) and the percent surface involved by fatty streaks was also signicantly smaller in the treated group (15.5±2%) than the control group (35.5±7%) (P<0.05), while there was no significant difference between both groups in the body weight, the weight of liver, heart, lung, brain, kidney, adrenal gland, and testis and in the serum cholesterol level.
The cAMP-level of atheromatous lesions and medial layers of the aortas of the placebo control animals exhibited an abnormally low level, while that of the healthy male adult rabbits was 3.43±0.21pmoles/mg D.W. and that of the treated group was 1.66±0.23pmoles/mg D.W. and was significangly higher than that of the placebo control group ((0.81±0.13)pmoles/mg D.W.) (p<0.05) and the cAMPPDE activity was abnormally elevated in atheromatous lesions and medial layers of the placebo control group and it was significantly lowered in the treated group (P<0.05) suggesting the possible significance of cAMPPDE inhibiting effect of EG626 in prevention of atherosclerosis.
